Objectives: There have been a numerous initiatives in Azerbiajan in recent years to improve antibiotic utilization including educational programmes among patients, pharmacists and physicians. This study aimed to analyse the influence of these multiple initiatives on antibiotic utilization as a basis for suggesting future initiatives.
Introduction
There are increasing concerns with the growing rates of antimicrobial resistance (AMR) across countries (1-3), with the resultant implications on morbidity, mortality and costs within countries. As a result, AMR has become one of the biggest public health challenges world-wide, with estimated deaths due to AMR reaching 444 million by the 2050 (4, 5), and estimated costs of €9 billion per year in Europe or higher (1, 2).
The occurrence and spread of AMR appears to correlate with increasing and irrational use of antibiotics (6) (7) (8) . This includes the self-purchasing of antibiotics across countries, including European countries, which is typically for viral infections such as upper respiratory tract infections (URTIs) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , with URTIs the predominant infection seen by physicians in ambulatory care (16) .
Currently in Azerbaijan, patients need a prescription to be dispensed an antibiotic as it is illegal for pharmacists to dispense antibiotics without a prescription. However, there has been variable enforcement of this law to date. This is not helped by the fact that patients in Azerbaijan typically having to cover the full cost of antibiotics themselves, even if they are prescribed by a physician. Consequently, it does not matter to them if the cost of the medicine is the same, and may even save on physician fees as patients must typically pay to see a physician. In addition, pharmacists may make a greater profit from dispensing an antibiotic rather than a OTC medicine such as paracetamol for a temperature associated with a viral infection. This though is beginning to change with greater scrutiny over pharmacy dispensing practices with penalties for abuse (Table 1 ). There are though exemptions to 100% co-payment. These include patients with AIDs and HIV, where treatment is funded via the Global Fund, patients with diabetes as well as patients with tuberculosis (TB) . Having said ths, there have been many activities over the years, especially in recent years, among all key stakeholder groups to encourage rational prescribing and dispensing of antibiotics in Azerbaijan.
As a result of the various initiatives in recent years (Table 1) , Azerbaijan in 2011 had the second lowest consumption of antibiotics among non-European Union (EU) southern and eastern European countries, and newly independent states, at 17.1 DIDs (DDDs per one thousand inhabitants per day), approximately half the rate seen in Turkey (8) . Encouragingly, Azerbaijan had the second highest use of beta lactam antibiotics as a percentage of total of antibiotic use, with a correspondingly low use of co-amoxiclav (0.3DIDs), low use of cephalosporins, as well as low use of fluorquinolones. There was also low use of long-acting macrolides (azithromycin) in Azerbaijan versus other European countries (8) .
However, it is important to see whether there is continued low, or even lower, use of antibiotics in Azerbaijan in recent years as well as continued low use of co-amoxiclav, cephalosporins and the fluorquinolones. High utilisation of co-amoxiclav increases side-effects from antibiotics, as well as resistance, resulting in co-amoxiclav typically recommended as second line after amoxicillin (19-23). There are also concerns with increasing use of cephalosporins, increasing resistance rates, rates of C. difficile, cardiac and other side-effects, as well as increasing the use and resistance to the fluoroquinolones (23-26). In addition, the WHO identified the fluoroquinolones, third-and fourthgeneration cephalosporins, macrolides and glycopeptides as being of the highest priority for risk management to improve future use (23).
There is also a need to record what reforms and initiatives have been instigated in Azerbaijan over the years to influence antibiotic utilisation. This is seen as particularly important to provide guidance to other similar countries that have higher use of antibiotics as well as concerns with high use of coamoxiclav, cephalosporins and fluoroquinolones.
We are aware that conditions such as childhood diarrhoea are an issue in Azerbaijan leading to 184 deaths per 100,000 children under five years, which is over twice the global average (27). However, targeted interventions including sanitation, nutrition, and hydration, have a greater influence on reducing mortality although antibiotics are indicated in certain situations (27) (28) (29) . In addition, Azerbaijan ranks 78 th out of 188 countries in their achievement of Sustainable Development Goals, higher than Turkey, Uzbekistan, Moldova, Macedonia and Serbia (30) , due to issues of childhood diseases, tuberculosis, high alcohol use, and the rise in non-communicable diseases (30) , However, some of these issues are not necessarily related to antibiotic use.
Consequently, the aim of this paper is to present and analyse total antibiotic consumption in Azerbaijan in recent years alongside ongoing initiatives to improve antibiotic use and reduce AMR. Subsequently, compare the findings with other similar European countries and former Soviet Union Republics to review potential additional measures that could be instigated in Azerbaijan if needed, as well as provide possible exemplars.
Methodology
This was a retrospective observational study of total antibiotic consumption in Azerbaijan from 2011 to 2015 based on import data. Import data on antimicrobials is provided each quarter by the wholesalers in Azerbaijan, with currently no breakdown by physician or pharmacist. Exact consumption data is currently only available for patients with HIV and TB as these medicines are provided free of charge.
Total antibiotic consumption was recorded as it is difficult to currently break these figures down into component parts within Azerbaijan. However, this is similar to surrounding European countries and former Soviet Union Republics (23).
The collection and analysis of data on drug consumption was undertaken using the ATC (Anatomical Therapeutic Chemical classification)/DDD (defined daily dose) methodology, with DDDs defined as the amount of the drug most commonly used in adults for the most common indication (8, 31, 32) . Utilisation data was further expressed in DIDs to compare utilisation rates across countries with different population sizes, similar for other diseae areas (8, 31, 33, 34) .
Key measures used to examine trends over time included relative consumption measures, expressed as a percentage of total consumption as well as specific antimicrobial agents within a class (23). The quality of antibiotic prescribing was assessed using the European Surveillance of Antimicrobial Consumption (ESAC), European Centre for Disease Prevention and Control (ECDC) and WHO quality indicators (8, 23, 35, 36) . These included:  Total utilisation of antibiotics expressed as DIDs  Utilisation of penicillins (J01C) in DIDs and as a % of total antibiotic use  % utilisation of combination penicillins such as co-amoxicav as a percentage of amoxycillin use  Total utilisation of cephalosporins ((J01D) in DIDs and as a % vs. total antibiotics  % utilisation of third-and fourth-generation cephalosporins vs first and second generation cephalosporins  Total utilisation of macrolides (J01F) in DIDs and as a % vs. total antibiotics  Utilisation of quinolones (J01M) expressed in DIDs as well as % vs. total antibiotic use We did not specifically review the utilisation of tetracylines as a quality indicator since, as mentioned, the WHO identified the fluoroquinolones, third-and fourth-generation cephalosporins, macrolides and glycopeptides as being of the highest priority for risk management to improve future use (23).
The findings in Azerbaijan were also compared to surrounding European countries and former Soviet Union Republics in 2011 and 2014 based on available data (8, 23), as well as European countries, especially Eastern European countries in the ECDC network in 2015 (36). These will be used to suggest additional measures within Azerbaijan to further improve the utilisation of antibiotics if pertinent acknowledging that we did not link antibiotic use to specific indications.
Since multiple initiatives and reforms were instigated over time with varying intensity, coupled with the problems with import data and their monthy fluctuations, it was impossible to undertake sophisticated statistical analyses such as time series analyses. As a result, more simple statistical tests, including trend analyses where possible, were performed to assess the level of significance, with significance seen as p <0.05. This is similar to other health authority analyses where multiple interventions are conducted over time with no opoortunity for time series analyses (33, 37-39).
No ethical approval was sought as this is a retrospective study of aggregated drug utilisation data.
Results
There have been various ongoing initiatives and measures in Azerbaijan over the years to try and improve antibiotic utilisation. These are captured in Table 1 building on initiatives in other countries (9, 40, 41) . [40, 41] ]. The objective being to reduce the marketing influence of pharmaceutical companies Pharmacists  Educating pharmacists nationwide that it is illegal to sell antibiotics without a prescription with inspectors regularly visiting pharmacists to monitor self-purchasing levels (as this still occurs) in addition to assessing the quality of medicines dispensed. This is undertaken during unscheduled and planned inspections of pharmacies by Ministry of Health officials to check them and educate pharmacists, i.e. in addition to quality checks on the medicines dispensed, checking prescription forms and monitoring the release of prescription drugs. Pharmacists are also remined about pertinent legislative acts and penalties for their violation to help reduce illegal selling of antibiotics  Included in the general campaigns in April and November (this includes antibiotic awareness week) as part of the drive to address selfpurchasing by educating pharmacists (and patients). This includes emphasising that most infections they see are typically viral in origin so do not require an antibiotic  It is likely that fines will start to be applied in Azerbaijan for illegal selling of antibiotics without a prescription, similar to other countries in the WHO Region such as the Republic of Srpska, Montenegro and Turkey [9] Patients  A key part of the general campaigns in April and November to try and reduce requests to physicians and pharmacists for antibiotics especially for suspected viral infections, which includes the majority of infections seen in ambulatory care  In 2014 -there was also a new pricing regulation to help reduce the costs of medicines to patients. Included within this was reference pricing within 5 categories. This reduced the number of manufacturers as well as available choices. In addition, reducing marketing activities among pharmaceutical companies  There are also further planned initiatives to enhance awareness of the dangers of inappropriate use of antibiotics among the public to reduce self purchasing of antibiotics and strengthen the message that antibiotics are only available via physicians. This will include multimedia campaigns
With respect to the new pricing regulation in 2014 (Table 1) , the Tariff Council now regulates wholesale and retail prices for all registered medicines based on competition and other factors. As indicated, all registered medicines have now been divided into 5 groups depending on the manufacturing country as Azerbaijan is an import-dependent country with very limited production of medicines. After the price adjustments, wholesalers and companies cannot sell medicines at the price they wish as there are now large fines if the pharmacy (via the wholesalers) sell medicines to patients not at regulated prices. This has appreciably reduced the profitability of companies. As a result, a number of companies have left the pharmaceutical market in Azerbaijan. However, lower prices can benefit patients. This has meant some antibiotic classes have lower prices than before such as the tetracyclines.
As a result, there has been a steady decline in total antibiotic consumption in Azerbaijan in recent years, which has reached significance when total use is combined (Table 2) . 
Discussion
It was encouraging to see a significant decline in the total antibiotic use in Azerbaijan in recent years (Table 2) , potentiallyt helped by the ongoing multiple and intergrated initiatives in Azerbajian, targeting all key stakeholders to moderate the prescribing and dispensing of antibiotics (Table 1 ). This appears similar to the findings of other studies regarding anti-infectives, and other disease areas, where multiple interventions have improved the rational use of medicines (33, 34, 37, 38, 42) . However, we cannot say this with certainty in this research due to the limitations of available data.
Overall, there was relatively low utilisation of antibiotics within Azerbajian, which compares favourably with other European countries and former Soviet Union Republics (Figure 3 Figure 1 ), may well be the result of the changes in the prices of pharmaceuticals following the reforms in 2014 and a number of companies no longer marketing their products (Table 1 ). This will be investigated further with concerns that penicillins are not being routinely used first line in for instance for suspected bacterial URTIs, which tend to be the commonest infections in ambulatory care (7, 16) .
There was typically low use of co-amoxiclav throughout the study period in terms of DIDs (Table 3) . However, the percentage versus total amoxycillins has been rising in recent years with 43% in 2014, which is high versus Tajikistan (2%) and Uzbekistan (12%), but similar to Albania (37%) and Kyrgyzstan (49%) and lower than Turkey (89%) in 2014 (23). Again, this will be investigated further. However, this is likely to be more a phenomenon of reduced amoxycillin use rather than appreciably increasing co-amoxiclav use given typically low utilisation, although rising in 2015 versus 2014 (Table  3) .
Whilst overall utilisation of the cephalosporins has remained relatively low in Azerbaijan at 6% of total antibiotic utilisation in 2014 (Figure 1 ) versus other former Soviet Union countries (23), there is concern with high utilisation of third generation cephalosporins in 2014 (Figure 2 ). This compares with only 16% in Serbia and 30% in Albania, but similar to 74% in Armenia and lower than 83% in Tajikistan in 2015 (23). Ceftriaxone is typically promoted by pharmaceutical companies as a convenient and effective cephalosporin (via personal communication), which we believe resulted in its high use among the cephalosporins over the years ( Figure 2 ). Further educational campaigns (Table  1) are now being implemented promoted by the Ministry of Health to try and reverse this high utilisation of ceftriaxone in favour of first and second generation cephalosporins. This is alongside measures to further regulate prices of the cephalosporins to increase the use of first and second generation cephalosporins at the expense of ceftriaxone. The impact of these initiatives will be explored further in future research projects.
There was also low use of the macrolides and other J01F antibiotics in Azerbaijan in 2014 at just 0. (Table 1) .
The planned introduction of electronic prescribing recording the prescribing and dispensing of antibiotics in ambulatory care should help to further improve antibiotic utilisation in Azerbaijan. This will include greater scrutiny over any self-purchasing of antibiotics as well as the potential introduction of quality and other indicators to improve future use. However, any introduction of quality indicators must be based on greater knowledge of the indications for current prescribing as well as greater knowledge of resistance rates, morbidity and mortality due to infectious diseases in Azerbaijan. This especially as there has been a marginal rise in deaths due to infection and parasitic diseases in Azerbaijan in recent years, rising from 472 in 2014, to 510 in 2015 and 564 in 2016 (43). In addition, investigating further issues of affordability regarding antibiotic use, especially if this deters the purchasing of antibiotics where there are appropriate indications adversely affecting patients. These are projects for the future along with the forthcoming instigation of a National Action Plan (NAP) to combat resistance to antimicrobials and its potential impact. The NAP will include greater knowledge of current resistance rates to guide additional activities.
There also needs to be initiatives to reduce the influence of pharmaceutical companies and their marketing (Table 1) , which can build on recent initiatives to enhance INN prescribing as well as further manipulate prices (Table 1 ).We will be monitoring these developments as well in the future.
Limitations
We acknowledge that there are several limitations with this study. Firstly, there can be unreliability with measuring utilisation via import data. However, the relative percentages and their comparisons with other similar countries provide guidance for the future in Azerbaijan and surrounding countries. Secondly, there is no data regarding accessability, availability or affordability of antibiotics and these issues could well have also influenced antibiotic consumption. Thirdly, there were no indicators of prescribing quality in relation to any diagnoses within the available data sets, and no data currently on resistance patterns to also assess appropriateness. Lastly, we are unable to comment on any changes in mortality as a result of changing prescribing patterns. Consequently, we cannot be fully confident that the changing antibiotic patterns we have seen are beneficial or not.
However, we believe our findings are robust and already leading to changes in Azerbaijan. This will continue.
Conclusion
There are encouraging signs regarding the utilisation of antibiotics in Azerbaijan in recent years, which may wellhave been facilitated by multiple educational and other activities among key stakeholder groups. However, further research is needed befoe we can make definitive statements. In the meantime, these activities are continuing to help to improve the appropriate use of antibiotics in Azerbaijn, alongside looking more critically at diagnoses.
There are some concerns, which include the high use of ceftriaxone among the cephalosporins as well as the growing use of tetracyclines in recent years, and these will be the target of further research and activities. Monitoring the future use of antibiotics should be helped by the introduction of electronic prescribing, and the introduction of INN prescribing should help reduce the influence of pharmaceutical companies.
Key Issues
 There have been multiple and intergrated initiatives involving all key stakeholders in Azerbaijan in recent years to improve antibiotic use. These initiatives have resulted in a significant reduction in total antibiotic use  Current utilisation of antibiotics in Azerbaijan in 2015 was 8.02 DIDs, the lowest among neigbouring countries  There was high use of beta lactam antibiotics over the years, in line with WHO and ECDC guidance; however, growing use of tetracyclines in 2015 at the expense of the penicillins as a result of new pricing policies is a concern  Overall low use of cephalosporins (although high use of third generation cephalosporins up to 85% of total cephalosporins), macrolides and quinolones in recent years is encouraging, especially when compared to neighbouring countries  Future initiatives are targeting the use of third generation cephalosporins as well as any remaining self-purchasing of antibiotics. INN and electronic prescribing should help with this, as well as further improve the quality of antibiotic prescribing in Azerbaijan in the future  The findings suggest that multiple initiatives can improve physician prescribing, in accordance with other published studies
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